Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). Here we show that 6 out of 16 melanoma tumours analysed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors. Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex determining region Y-box 10 (SOX10) in melanoma causes activation of TGF-β signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-β (PDGFRB), which confer resistance to BRAF and MEK inhibitors. Expression of EGFR in melanoma or treatment with TGF-β results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence. However, EGFR expression or exposure to TGF-β becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors. In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples. Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated that in BRAF V600E mutant cancers, BRAF inhibition can lead to rapid EGFR-mediated feedback activation [95,96,104].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Cited by
Items 701–800 of 916
Emerging Drug Combination Approaches in Melanoma Therapy
Wang, J., Miller, D. D., & Li, W. (2015) · InTech eBooks · doi:10.5772/59360 · Cited by 2
“In vitro and murine models first show the synergistic anti-proliferation and antitumor growth effects using the combined BRAFi and MEKi treatment [9, 27, 38, 39].”
BackgroundInfluentialA higher proportion of craniosynostosis genes are cancer driver genes
Misra, S., Shih, A., Yan, X., & Li, W. (2025) · Human Gene · doi:10.1016/j.humgen.2025.201378 · Cited by 2
Pluetrattanabha, N., Direksunthorn, T., Ahmad, I., Jyothi, S. R., Shit, D., Singh, A. K., & Chauhan, A. S. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-025-03802-1 · Cited by 2
“On the other hand, the emergence of primary resistance in melanoma can be ascribed to the confluence of considerable modifications in the microenvironment of tumour cells and genetic and epigenetic alterations [97, 98].”
NSD2 and miRNAs as Key Regulators of Melanoma Response to Romidepsin and Interferon‐α2b Treatment
Santis, A. D., Santis, L. D., Rossi, F., Gasparini, S., Licursi, V., Amico, V. A., Capone, I., Fragale, A., D’Atri, S., Gabriele, L., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70917 · Cited by 2
Alobuia, W. M., & Pawlik, T. M. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2570163 · Cited by 3
Treatment for metastatic melanoma: a new and evolving era
Sousa, R., Cortes, P., Harries, M., & Papa, S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12583 · Cited by 3
Vella, L. J., Andrews, M. C., Behren, A., Cebon, J. S., & Woods, K. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.929943 · Cited by 2
“This has been attributed to the development of resistance through any number of now well-described mechanisms [5–7].”
BackgroundPersonalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy
Zänker, K. S., Børresen‐Dale, A., & Huber, H.-P. (2016) · Biomedicine Hub · doi:10.1159/000453253 · Cited by 2
Рябая, О. О., Малышева, А. А., Хоченкова, Ю. А., Solomko, E. S., & Khochenkov, D. A. (2018) · Molecular Biology · doi:10.7868/s0026898418030096 · Cited by 2
Ryabaya, O. O., Малышева, А. А., Khochenkova, Y. A., Solomko, E. S., & Khochenkov, D. A. (2018) · Molecular Biology · doi:10.1134/s0026893318020115 · Cited by 2
“Tumor cells start to overexpress PDGFRβ [10] and PDGFRα [14]; EGF receptor feedback is activated [28]; stromal cells surrounding the tumor secrete the hepatocyte growth factor [29].”
BackgroundYue, C., Lian, W., Fan, Z., Li, H., Duan, M., Qin, L., Cao, X., & Peng, J. (2023) · Environmental Toxicology · doi:10.1002/tox.24017 · Cited by 2
“29 Pleckstrin homology domain-containing A7 (PLEKHA7), a component of the zonula adherens (ZO-1), is required for the tumor-suppressing function of E-cadherin in polarized epithelia (ZA).”
BackgroundRetractedAJP-Cell Theme on “Cell Signaling: Proteins, Pathways and Mechanisms”
Adams, J. C. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.7685-editorial.2015 · Cited by 2
Ho, Y.-J., Anaparthy, N., Molik, D. C., Aicher, T. P., Patel, A. K., Hicks, J. B., & Hammell, M. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/239319 · Cited by 2
Zhang, Y., Belote, R. L., Urquijo, M. A., Hansen, M. M. K., Hejna, M., Moustafa, T. E., Liu, T., Lange, D., Vand‐Rajabpour, F., Chang, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.26.269126 · Cited by 3
Lattmann, E., Jovic, A., Kim, J. J., Pham, T., Corona, C., Lian, Z., Saini, K., Ray, M., Lu, V., Tastanova, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.28.601235 · Cited by 2
The Fitness Cost of Therapeutic Resistance in Cancer: A Systematic Review
Kane, B. S., Mestas, L., Garza, M., Soesilo, T., Hufford, M., Richker, H. I., & Maley, C. C. (2026) · Evolution Medicine and Public Health · doi:10.64898/2025.12.29.696883 · Cited by 3
Chen, J., Zhai, J., Li, M., Liu, S., Gong, X., Yu, H., Wei, H., & Chen, W. (2023) · Cancer Cell International · doi:10.1186/s12935-022-02723-7 · Cited by 1
“BRAF protein is a critical kinase in the mitogen-activated protein kinase (MAPK) signaling pathway, encoded by the BRAF gene, activating downstream MEK and ERK signal pathway-related proteins and can regulate cell proliferation, differentiation and apoptosis [23, 24].”
BackgroundChen, L., Pruteanu-Malinici, I., Dastur, A., Yin, X., Frederick, D. T., Sadreyev, R. I., & Benes, C. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-86694-5 · Cited by 1
“…more broadly, such as SOX10 , whose downregulation leads to elevated EGFR and PDGF receptor signals and increased resistance to BRAF inhibition 9 ; MIA , which is involved in melanocyte lineage and melanoma development 42,43 ; and ERBB3 , which can reactivate MAPK upon MEK inhibition through…”
A Co-essentiality Network of Cancer Driver Genes Better Prioritizes Anticancer Drugs
Lee, K., Kim, D., Kim, I., Lee, J.-H., Ha, D., Lim, S., Kim, E., Im, S., Shin, K., & Kim, S. (2025) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzaf070 · Cited by 2
“For example, in SKCM, a biomarker of Vemurafenib [47], SOX10 , ranked 34th in the co-essentiality network, but 9695th in the PPI network, 6688th in the co-expression network, and 3461st in the co-methylation network (Figure 3D).”
Kluitmans, D. J. F., Melis, J. J. T. M., van den Bossche, E., Ytsma, J., de Roos, J. A. D. M., van Linden, O. P. J., Grobben, Y., Kooijman, J. J., & Zaman, G. J. R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1667291 · Cited by 1
Solé-Blanch, C., España, S., de la Puente-Noël, A., Marín-Béjar, O., Manzano, J. L., & Martínez‐Cardús, A. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189503 · Cited by 1
Qi, G., Wang, L., Nan, M., Fu, Y., Ren, Q., Zhang, Y., Sun, Z., Shi, Z., Lu, J., & Gao, J. (2026) · Communications Biology · doi:10.1038/s42003-025-09418-5 · Cited by 2
“In cancer treatment, a “ drug holiday ” refers to the planned or intermittent cessation of anticancer drugs, which may delay resistance and restore drug sensitivity 45 .”
Self-citationHarb, N., Romey, M., Grass, A., von Kügelgen, F., Hattesohl, A., Schäfer, J., Frey, L., Mack, E., Rinke, A., Brendel, C. A., et al. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.04.001 · Cited by 1
Styczewska, M., Łyzińska, W., Krawczyk, M. A., & Bień, E. (2026) · Oncology Reviews · doi:10.3389/or.2026.1815932 · Cited by 1
“Emerging data also suggest that MAPK inhibition may induce adaptive cellular states, including increased cellular plasticity and transcriptional reprogramming toward a progenitor-like phenotype, which could facilitate rapid tumor regrowth upon drug withdrawal (58, 59).”
Targeted therapy in melanoma: the era of personalized medicine
Naert, K. A., Habeeb, A. A., Gedye, C. A., & Ghazarian, D. (2014) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2014.10.001 · Cited by 1
[Hypercalcinosis of the hands in scleroderma. 2 case reports].
Eckardt, J., & Towfigh, H. (1994) · PubMed · Cited by 1
Melanoma Genetics and Genomics
Ho, A., Jönsson, G. B., & Tsao, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-41319-8_4 · Cited by 1
Cancer as a Paradigm for Translational and Clinical Biomedical Research
Serrano, C., & Demetri, G. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00032-6 · Cited by 1
Самойленко, И. В., Жуликов, Я. А., & Демидов, Л. В. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-14-6-10 · Cited by 1
“показали восстановление чувствительности к ингибиторам BRAF или MEK после «лечебного отпуска» [5].”
Signal Transduction in Disease
Ganey, P. E., & Misek, S. A. (2019) · Wiley eBooks · doi:10.1002/9781119060208.ch4 · Cited by 1
Dal'Ava, B. T., de Souza, N. F., Chagas, T. D. S., & Pereira, G. J. V. (2022) · Research Society and Development · doi:10.33448/rsd-v11i14.36275 · Cited by 1
PERSONALIZED APPROACH TO ADJUVANT CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Tsyganov, M. M., Родионов, Е. О., Ibragimova, М. K., Тузиков, С. А., & Litvyakov, N. V. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.32 · Cited by 1
Bocharova, O. A., Карпова, Р. В., Бочаров, Е. В., Aksenov, A. A., Chulkova, S. V., Kucheryanu, V. G., Kazeev, I. V., Revischin, A., Pavlova, G. P., Shevchenko, V. E., et al. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.17 · Cited by 1
The impact of c-Met inhibition on molecular features and metastatic potential of melanoma cells
Demková, L., Matúšková, M., Gercakova, K., Kozovská, Z., Smolková, B., & Kučerová, L. (2024) · Neoplasma · doi:10.4149/neo_2024_240523n232 · Cited by 1
TGF-β Signaling Pathway and Its Therapeutic Role in Cancer
James, A. W., Bhat, H. M., Yousuf, S., Jan, M., Rehman, M. U., & Rashid, S. M. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_11 · Cited by 2
Liu, X., Mi, J., Qin, H., He, S., Li, Z., Chai, J., Li, M., Xu, J., & Wu, J. (2020) · International Journal of Dermatology and Venereology · doi:10.1097/jd9.0000000000000107 · Cited by 1
“They transport the received extracellular stimuli into cells to trigger signaling cascades, thus regulating cell survival, proliferation, differentiation, apoptosis, and migration.1 Mutations and/or amplifications of RTK genes have been reported to contribute to the tumorigenesis and progression of many cancers.21-22…”
BackgroundTargeting Nrf2 in inflammation and cancer
Cowan, J. (2014) · UEA Digital Repository (University of East Anglia) · Cited by 1
Buffet, C. (2014) · theses.fr (ABES) · doi:10.70675/ddd9166ez4567z4211z8b40z563419a60629 · Cited by 2
“Un schéma d’administration discontinue du vemurafenib permettait, dans un modèle de xénogreffe de lignées cellulaires humaines de mélanome mutées pour B-RAF et dans des panels de lignées de mélanomes mutés pour B-RAF, de prévenir le développement de résistance [149, 160, 178].”
BackgroundTargeted BRAF inhibitors: Immunological effects and combination with immunotherapy
Cameron, A. M. (2015) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17013803 · Cited by 1
A Look Inside of the Complex Pathogenesis of B-RAF(V600E)-Driven Cancer
Caputo, E. (2017) · Theranostics · doi:10.7150/thno.20460 · Cited by 1
“However, responses were largely partial, and clinical evidences of tumor resistance were observed, due to the activation of adaptive mechanisms switched on from cancer cells upon the drug selective pressure as well as consequence of the intrinsic tumor cell plasticity potential (2, 3).”
BackgroundHan, H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2021) · Research Square · doi:10.1101/2021.04.14.439569 · Cited by 1
“Integrated RNA-seq and ATAC-seq followed by ChIP-seq provided evidence that the LNCaP cells acquire mesenchymal and stem-like traits and become tolerant to enzalutamide through epigenetic reprogramming, as it has been proposed for melanoma cells exposed to vemurafenib (Shaffer et al., 2018; Sun et al., 2014).”
MethodPropranolol-induced apoptosis via the AKT signaling pathway in epithelial ovarian cancerPreprint
Yin, T., Chen, Y., Liu, F., Lai, X., Wang, X., & Zhu, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-2332936/v1 · Cited by 1
Protein Kinases in the Era of Precision Medicine
Moiani, D., Tabaian, A., Suto, R. K., Doyle, D. M., & Sowadski, J. M. (2015) · Wiley eBooks · doi:10.1002/9780470015902.a0000659.pub3
Alderton, G. K. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3739
Optimizing the treatment of BRAF mutant melanoma
Settleman, J. (2014) · Genome Medicine · doi:10.1186/gm547
“Interestingly, these investigators [9] had also observed that EGFR expression in BRAF mutant melanoma cells was surprisingly detrimental to their proliferative capacity, and was only tolerated in the context of BRAF inhibition.”
BackgroundInfluentialErdem‐Eraslan, L., Gao, Y., Kloosterhof, N. K., Atlasi, Y., Demmers, J., Sacchetti, A., Kros, J. M., Smitt, P. A. E. S., Aerts, J. G. J. V., & French, P. J. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou242.5
Quoi de neuf en cancérologie cutanée ?
Jouary, T. (2014) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(14)70167-x
Barkovskaya, A. (2015) · NVA (Nasjonalt vitenarkiv)
New Treatments for Advanced Melanoma
Uhara, H. (2016) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.78.5
Identification of Predictive Response Markers and Novel Treatment Targets for Gliomas
Erdem‐Eraslan, L. (2016) · RePub (Erasmus University Rotterdam)
Wang, J. (2015) · doi:10.21007/etd.cghs.2015.0341
“In addition, several ongoing phase I/II clinical trials now have shown that generally the combination of other BRAFi and MEKi is well tolerated in patients with or without receiving BRAFi treatment before (ClinicalTrials.gov, NCT01271803 7 vemurafenib (BRAFi) + cobimetinib (MEKi), NCT01543698 LGX818 (BRAFi) + MEK162 (…”
InfluentialAyyıldız, Z. Ö. (2014) · Bilkent University Institutional Repository (Bilkent University)
The Many Faces of the Paradoxical Response to BRAF Inhibitors
Merat, R. (2017) · Clinical skin cancer · doi:10.1016/j.clsc.2017.07.003
Targeting B-RAF Mutated Sarcomas
Gouravan, S. (2017) · NVA (Nasjonalt vitenarkiv)
Combating malignant melanoma with the multifaceted soy-dervied peptide lunasin.
Shidal, C. (2017) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2713
“9 feedback activation of epithelial growth factor receptor (EGFR), upregulation of other Raf proteins, or upregulation of N-Ras [85-87].”
BackgroundRunning INTERFERONce on immunotherapy
Rosenbaum, S. R., & Aplin, A. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12663
“This finding is important because SOX10 silencing can play a role in mediating adaptive resistance to BRAF inhibitor targeted therapy (Sun et al., 2014), and these results indicate that it may play additional roles in sensitizing cancer cells to T- cell- mediated killing.”
BackgroundMittermeier, C. (2017) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.21594
Neyra, J. M. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2018.tde-30012018-101101
Mardis, E. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-816061-9.00007-2
Meierjohann, S., & Schilling, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00046-6
Dabrafenib plus trametinib rechallenge for malignant melanoma of the head in a 17-year-old woman
Miura, S., Onishi, M., Nakagawa, M., Tsunoda, K., SATOU, R., Baba, S., Maeda, H., & Amano, H. (2019) · Skin Cancer · doi:10.5227/skincancer.33.206
Circulating Tumor DNA Analysis and Opportunities for Personalized Cancer Medicine
Farooq, M., & Murtaza, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813539-6.00011-0
Targeted Therapies for BRAF-Mutant Metastatic Melanoma
Johnson, D. B., Dummer, R., Flaherty, K. T., & Smalley, K. S. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-46029-1_40-1
Wong, T. C. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Rôle de MITF et du métabolisme des sphingolipides dans le mélanome cutané
Leclerc, J. (2019) · theses.fr (ABES) · doi:10.70675/e6ceb3b4z96a2z4196za809z97cd83844103
Sequencing methods in dermatology
Аксененко, М. Б., & Ruksha, T. G. (2016) · Russian Journal of Skin and Venereal Diseases · doi:10.18821/1560-9588-2016-19-1-7-12
Mechanisms of Resistance to Targeted Therapies in Skin Cancers
Czarnecka, A. M., Fiedorowicz, M., & Bartnik, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_18
Flatz, L., Ring, S. S., Pop, O. T., Poźniak, J., Berner, F., Ali, O. H., Abdou, M.-T., Diem, S., Bomze, D., Niederer, R., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-403313/v1
Dubose, E. S. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/bz1q-qe86
Translational research of combined anticancer therapies targeting the MAPK pathway
Huijberts, S. C. F. A. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/1019
Cultural Perspectives on China Resolving Disputes Through Mediation
Lawless, N. (2008) · TDM
Transcriptional Regulation in Melanoma
Yokoyama, S., & Fisher, D. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-41319-8_5
Altered Signal Transduction Pathways in Melanoma
Chéli, Y., Lau, E. K., & Ronai, Z. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-41319-8_7
Targeted Therapies for BRAF-Mutant Metastatic Melanoma
Johnson, D. B., Dummer, R., Flaherty, K. T., & Smalley, K. S. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_40
Heinzerling, L., Hartmann, A., & Hund, M. (2019) · Springer eBooks · doi:10.1007/978-3-662-58012-7_1
A Systems Approach to Overcome Tumor-cell Heterogeneity in Drug Response: Metrics and Mechanisms
Comandante-Lou, N. (2022) · Deep Blue (University of Michigan) · doi:10.7302/5949
Mayorova, V. E., Mollaev, M. D., Вихрева, П. Н., Kulakovskaya, E. A., Pershin, D., Кибардин, А. В., Maschan, M. A., & Larin, S. S. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.35
ANALYSIS OF IMMUNOHISTOCHEMICAL REACTIONS OF VARIOUS PD-L1 CLONES IN PROSTATE ADENOCARCINOMA
Kalfa, М. А., Golubinskaya, E. P., Makalish, T. P., Zyablitskaya, E. Y., & Kubyshkin, A. V. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.38
Frantsiyants, E. M., Surikova, E. I., Bandovkina, V. A., Kaplieva, I. V., Pogorelova, Y. A., Neskubina, I. V., Cheryarina, N. D., Trepitaki, L. K., Морозова, М. И., Kotieva, I. M., et al. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.28
FEATURES OF EXPRESSION OF TRANSFORMING GROWTH FACTOR BETA IN ESTROGEN-POSITIVE BREAST CANCER
Анатольевна, Д. Т., Николаевна, Б. Н., Slonimskaya, E. M., & Cherdyntseva, N. V. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.33
MECHANISMS OF RESISTANCE IN THERAPY WITH ANGIOGENESIS BLOCKERS IN COLORECTAL CANCER
Golubinskaya, E. P., Seferov, B. D., Kalfa, М. А., Фомочкина, И. И., & Kubyshkin, V. А. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.37
CIRCULATING DISIALOGANGLIOSIDE GD2 IN NEUROBLASTOMA DIAGNOSIS
Mollaev, M. D., Ivanov, N. S., Литвин, Е. А., Kara, V. V., Kholodenko, R. V., Maschan, M. A., Kachanov, D. Y., Shamanskaya, T. V., & Larin, S. S. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.34
Molokov, A. Y., Анатольевна, Г. П., Zarubin, А. А., Тихонов, Д., & Cherdyntseva, N. V. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.39
Khripko, O. P., Khripko, Y. I., Deulin, I. Y., Владимировна, К. Е., & Zakharov, V. N. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.40
Игоревна, Л. М., Вихрева, П. Н., Кибардин, А. В., Maschan, M. A., & Larin, S. S. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.36
Popova, N. N., Shikhlyarova, A. I., Rozenko, D. A., Вартанович, Т. С., Shepelenko, A. V., Korobov, A. А., Netyvchenko, N. V., Sugak, E. Y., & Ardzha, A. Y. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.29
LITHIUM EFFECT ON AUTOPHAGY AND CELL DEATH IN SKIN MELANOMA
Taskaeva, I. S., Gogaeva, I., Shatruk, A., & Bgatova, N. P. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.14
RADIODYNAMIC AND CONTACT RADIATION THERAPY OF INOCULATED TUMOR IN AN IN VIVO EXPERIMENT
Tserkovsky, D. A., Protopovich, E. L., Mazurenko, A. N., & Borichevsky, F. F. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.3
ENERGY PHENOTYPES OF BT20, BT474, MDA-MB-453 UNDER ACTIONS AND EFFECTS MADE BY BERBERINE
Timofeeva, S. V., Filippova, S. Y., Sitkovskaya, A. O., Межевова, И. В., Enin, Y. S., Shamova, T. V., & Гненная, Н. В. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.20
THE IMMUNE SYSTEM AND MALIGNANT NEOPLASMS: FUNDAMENTAL AND TRANSLATIONAL ASPECTS
Cherdyntseva, N. V., Анатольевна, Г. П., Ivanyuk, E. E., Ivanova, A. A., Molokov, A. Y., Ponomareva, A. A., Ermak, N. E., & Buldakov, M. A. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.7 · Cited by 37
GALLO-ELLAGI-TANNINS OF CHAMAENERION ANGUSTIFOLIUM: ANTITUMOR ACTIVITY
Sasov, S. A., Totoeva, N. N., Фадеев, Н. Б., Масляков, В. Ю., & Gusev, D. V. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.23
IMPLEMENTATION OF THE PRINCIPLES OF ACTIVATION ELECTROMAGNETOTHERAPY IN EXPERIMENTAL ONCOLOGY
Zhukova, G. V., Shikhlyarova, A. I., Sheĭko, E. A., Gudtskova, T. N., Zernov, V. A., & Rudenko, M. Y. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.6
ABNORMALITIES IN NATURAL LIGHT REGIMEN AS TRIGGER OF TUMOR GROWTH
Vinogradova, I. A., & Anisimov, V. N. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.24
EXTRACELLULAR MATRIX OF EXPERIMENTAL HEPATOCARCINOMA G-29 UNDER THE INFLUENCE OF LITHIUM CARBONATE
Makarova, V. V., & Bgatova, N. P. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.25
PDX MODEL OF BC IN THE STUDY OF PLASTICITY OF TUMOR CELLS IN THE PROCESS OF METASTASIZING
Bokova, U. A., Tretyakova, M. S., Frolova, A. A., Валерьевич, А. В., Сергеевна, А. Е., Cherdyntseva, N. V., Михайлович, П. В., & Владимирович, Д. Е. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.4
SELF-DEPENDENT ANTITUMOR EFFECTS PRODUCED BY METAL-CONTAINING NANOPARTICLES IN IN VIVO EXPERIMENTS
Zhukova, G. V., Goroshinskaya, I. A., Kachesova, P. S., Zlatnik, E. Y., Shikhlyarova, A. I., Zernov, V. A., Rudenko, M. Y., Novikova, I. A., & Kit, O. I. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.15
EVALUATION OF CYTOTOXICITY AND PRO-APOPTOTIC EFFECTS OF NEW CYP17A1 INHIBITORS
Khan, I. I., Aidosov, C. M., Krivchenko, V. O., Latysheva, А. S., Zolottsev, V. А., Misharin, A. Y., & Pokrovsky, V. S. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.19
Metadata
- Authors
- Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F. A., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. M., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Institut Gustave Roussy (FR)
- Candiolo Cancer Institute (IT)
- IFOM (IT)
- ORCID
- Sun, Chong
- Wang, Liqin
- Huang, Sidong
- Heynen, Guus J. J. E.
- Prahallad, Anirudh
- Robert, Caroline
- Haanen, John
- Blank, Christian
- Wesseling, Jelle
- Willems, Stefan M.
- Zecchin, Davide
- Lieftink, Cor
- Hofland, Ingrid
- Schlicker, Andreas
- Wessels, Lodewyk F. A.
- Beijersbergen, Roderick L.
- Bardelli, Alberto
- Eggermont, Alexander M. M.
- Venue
- Nature
- Published
- 2014-03-26
- Volume
- 508
- Issue
- 7494
- Pages
- 118-122
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985928174
- Cited by
- 888
- References
- 30
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 62 · 2023: 58 · 2022: 90 · 2021: 81 · 2020: 71 · 2019: 76 · 2018: 75 · 2017: 83 · 2016: 71 · 2015: 107 · 2014: 39
- FWCI
- 40.97
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP130540)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- BRAF inhibitor resistance, SOX10, TGF-beta signaling, PDGFRβ, oncogene-induced senescence, drug holidays, MEK inhibitors, adaptive resistance, shRNA screen, cell proliferation, tumor heterogeneity, drug re-sensitization, receptor tyrosine kinase
- MeSH terms
- Vemurafenib, Animals, Antineoplastic Agents, Female, Flow Cytometry, Humans, Indoles, Melanoma, Sulfonamides, Signal Transduction, Gene Library, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Cellular Senescence, Drug Resistance, Neoplasm, Receptor Protein-Tyrosine Kinases, Receptor, Platelet-Derived Growth Factor beta, Mitogen-Activated Protein Kinase Kinases, RNA, Small Interfering, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, SOXE Transcription Factors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.